Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

15 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Infectious Bronchitis Virus (IBV) Infection

ABSTRACT: Infectious bronchitis virus (IBV), is a coronavirus which infects chickens (Gallus gallus), and is one of the foremost causes of economic loss within the poultry industry, affecting the performance of both meat-type and egg-laying birds. The virus replicates not only in the epithelium of upper and lower respiratory tract tissues, but also in many tissues along the alimentary tract and elsewhere e.g. kidney, oviduct and testes. It can be detected in both respiratory and faecal material. There is increasing evidence that IBV can infect species of bird other than the chicken. Interestingly breeds of chicken vary with respect to the severity of infection with IBV, which may be related to the immune response (Cavanagh, 2006). Here we examine differential expression of genes in the trachea of susceptible and resistant birds, in order to identify genes which may be involved in resistance to IBV.

ORGANISM(S): Gallus gallus

SUBMITTER: Jacqueline Smith

PROVIDER: E-TABM-1128 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Infectious Bursal Disease Virus (IBDV) Infection

Project description:Infectious bursal disease virus (IBDV) is a highly contagious dsRNA virus (Birnaviridae) which causes immuno-suppression in chickens. Although largely controlled by vaccination, new, virulent strains of the virus mean that infectious bursal disease (IBD or ëGumboroí disease) still remains a threat to the poultry industry. The virus infects dividing IgM+ B-lymphocytes and the main site of viral replication is the bursa of Fabricius where B cells are produced. Infection is spread orally via contaminated feed and water. IBDV affects young birds, with the disease usually being diagnosed in 3-6 week old birds. Younger birds do not show clinical signs but are immuno-suppressed. Symptoms include anorexia, depression, diahorrea, ruffled feathers, immuno-suppression and bursal lesions. The disease peaks between 2-5 days post infection and is practically cleared by day 7. Mortality is variable but can be up to around 70% with very virulent strains of the disease. Even if birds survive, the resulting immuno-suppression and effect on egg production in layer birds is significant. Being able to breed commercial lines of birds for enhanced genetic resistance to IBDV is an obvious goal in the fight against the disease. Three-week-old chicks were inoculated with virus via an intra-nasal route and tissue samples were collected at 2, 3 and 4 days post-inoculation. Bursa and spleen tissues were examined from control and infected birds at 2, 3 and 4 days post-infection in birds known to be either susceptible or resistant to the virus. As well as understanding the host immune response to IBDV, we are interested in identifying genes involved in disease resistance and so we have analysed the gene expression profiles at these times, when the innate immune response is active. We assume that genes underlying resistance will be involved at this early stage of the host immune response.

2014-12-30 | E-TABM-1129 | biostudies-arrayexpress

Transcription profiling of human cell line alveolar type II A549 ingected with HRSVs, time series

Project description:Microarray technology was used to monitor the level of expression of 9,300 human genes at different time-points after infection of the type II alveolar A549 human cell line with HRSVs.

2006-07-30 | E-TABM-79 | biostudies-arrayexpress

Transcription profiling of human Chronic Lymphocytic Leukemia samples

Project description:Microarray technology was used to predict the outcome of Chronic Lymphocytic Leukemia

2007-09-04 | E-TABM-80 | biostudies-arrayexpress

Transcription profiling of diagnostic tumoral samples in relation to primary response to drug treatment

Project description:Expression profile of diagnostic tumoral samples in relation to primary response to drug treatment

2005-10-30 | E-MEXP-388 | biostudies-arrayexpress

Transcription profiling of patients with diffuse large B-cell lymphoma who do or do not respond to treatment to identify biological markers of sensivity to high-clinical-risk-adapted therapy

Project description:Microarray technology was used to identify new predictive biomarkers in samples of clinically homogeneus patients.

2008-10-26 | E-TABM-364 | biostudies-arrayexpress

Transcription profiling of human nodal peripheral T-cell lymphomas

Project description:Microarray technology was used to monitor the level of expression of 7,657 human genes in a set of 35 nodal peripheral T-cell lymphomas.

2007-01-30 | E-TABM-191 | biostudies-arrayexpress

Transcription profiling and idenrification of gene expression signatures associated with favourable or unfavourable treatment response and clinical outcome of Hodgkin lymphoma patients

Project description:Identification of gene expression signatures associated with favourable or unfavourable treatment response and clinical outcome of Hodgkin lymphoma patients.

2006-06-01 | E-MEXP-507 | biostudies-arrayexpress

Transcription profiling by array of mouse embryonic stem cells expressing the transcription factor NGN3 for 12 hours, 24 hours and 48 hours

Project description:A mouse embryonic stem cell line was generated which stably expressed the ngn3 transcription factor under the control of the Tet-On inducible system using knock-ins in the ROSA26 and the HPRT loci. The undifferentiated mouse embryonic stem cells were then differentiated into Embryoid Bodies in suspension culture and were either treated with Doxycycline to induce NGN3 expression or left untreated as a contol. Cells were harvested at 12 hours, 24 hours and 48 hours.

2007-09-01 | E-MIMR-461 | biostudies-arrayexpress

Transcription profiling validation of an custom mouse oligo array using liver samples following treatment with the hepatotoxin phenobarbital and variable hybridization protocols

Project description:The use of custom-made focused microarrays has become a popular alternative, allowing the study of genes relevant to a specific hypothesis. To address the limitations of commercial arrays in toxicogenomics investigations, we have developed a custom mouse oligonucleotide microarray, the HC ToxArrayTM, which, by virtue of including genes that respond to a variety of chemical and physical stressors, is more relevant for toxicological studies. Furthermore, we have incorporated an extensive series of controls useful for both quality control and normalization of small focused arrays. Validation of the EC series for normalization was achieved by determining the gene expression profile in liver samples following treatment with the hepatotoxin phenobarbital. Technical variability experiments were also carried out by two different technicians using two hybridization methods (automated and manual) and compared. In this study, we demonstrate that dilution of oligonucleotides on the microarray itself provides an innovative approach allowing the full dynamic range of the scanner to be covered with a single gene spike-in. The dilution series can be used in a composite normalization to improve detection of differential gene expression and provide quality control measures.

2006-10-30 | E-MEXP-525 | biostudies-arrayexpress

Transcription profiling of BXH/HXB rat recombinant inbred strains derived from the spontaneously hypertensive rat (SHR/Ola) and the Brown Norway congenic strains carrying the polydactylyl-luxate mutation (BN-Lx)

Project description:BXH/HXB rat recombinant inbred (RI) strains are derived from the spontaneously hypertensive rat (SHR/Ola) and the Brown Norway congenic strains carrying the polydactylyl-luxate mutation (BN-Lx). Tissue from the apex of left ventricle of the heart was disected from 128 RI SHR/Ola and BN-Lx parental strains, RNA was extracted and labelled and hybridised to Affymetrix Rat Genome 230 2.0 Arrays.

2008-04-01 | E-MIMR-222 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data